WebFirst Baptist Church of Glenarden, Upper Marlboro, Maryland. 147,227 likes · 6,335 talking about this · 150,892 were here. Are you looking for a church home? Follow us to learn … WebMar 21, 2024 · Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver … GAITHERSBURG, Md. , Feb. 21, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. … Events and Presentations - Altimmune – Investors Overview SEC Filings - Altimmune – Investors Overview In The News - Altimmune – Investors Overview Analyst Coverage - Altimmune – Investors Overview Stock Quote & Chart - Altimmune – Investors Overview Email Alerts - Altimmune – Investors Overview Annual Reports - Altimmune – Investors Overview Investment Calculator - Altimmune – Investors Overview
Altimmune Reports Data from its Phase 1b Clinical Trial of …
WebSep 14, 2024 · Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver … WebJun 1, 2024 · Altimmune will host a conference call and webcast to discuss T-COVID on Monday, June 1, 2024 at 8:30 a.m. Eastern Time. The conference call will be accessible by dialing (877) 423-9813 (US/Canada ... great trench
Events and Presentations – Altimmune
WebSep 13, 2016 · GAITHERSBURG, Md., Sept. 13, 2016 (GLOBE NEWSWIRE) -- Altimmune, Inc., a clinical stage immunotherapeutic company, today announced that Christine Brennan, PhD, Principal at Novartis Venture... WebAug 21, 2024 · Altimmune has raised a total of $51.4M in funding over 4 rounds. Their latest funding was raised on Aug 21, 2024 from a Grant round. Altimmune is registered under the ticker NASDAQ:ALT . Altimmune is funded by 5 investors. Biomedical Advanced Research and Development Authority (BARDA) and HealthCap are the most recent investors. WebJan 31, 2024 · Altimmune—a clinical-stage biopharmaceutical company—has announced the US Food and Drug Administration has cleared the company’s investigational new drug (IND) application for a Phase II clinical trial of pemvidutide. The drug is an investigational GLP-1/glucagon dual receptor agonist under development for the treatment of obesity and non ... florida blue foundation conference